https://regulations.justia.com/regulations/fedreg/agencies/office-of-the-secretary/2017/06/20?registers=between Sat, 18 May 2024 02:07:46 -0700 Sat, 18 May 2024 02:07:46 -0700 Justia Regulations Tracker Copyright 2011 Justia Inc. https://regulations.justia.com/images/justiafedregulations.gif https://regulations.justia.com/regulations/fedreg/agencies/office-of-the-secretary/2017/06/20?registers=between https://regulations.justia.com/regulations/fedreg/2017/06/20/2017-12840.html https://regulations.justia.com/regulations/fedreg/2017/06/20/2017-12840.html Tue, 20 Jun 2017 00:00:00 -0700 2017-12840 Notice https://www.gpo.gov/fdsys/pkg/FR-2017-06-20/pdf/2017-12840.pdf https://regulations.justia.com/regulations/fedreg/2017/06/20/2017-12774.html https://regulations.justia.com/regulations/fedreg/2017/06/20/2017-12774.html Tue, 20 Jun 2017 00:00:00 -0700 2017-12774 Notice https://www.gpo.gov/fdsys/pkg/FR-2017-06-20/pdf/2017-12774.pdf https://regulations.justia.com/regulations/fedreg/2017/06/20/2017-12744.html https://regulations.justia.com/regulations/fedreg/2017/06/20/2017-12744.html 50% Figure 4D results for the inhibition by UNC10112646, UNC10225354, and UNC10225498, in dose response assays against the kinase domain of PPIP5K Figures 5A and 5B results for isothermal titration calorimetry (ITC) assays for quantifying intermolecular interactions between PPIP5K and the inhibitors, UNC1011264 and UNC10225498, and Figure S5 for UNC10225354 Figure 6 results for the analysis of the mechanisms of inhibition of PPIP5K by UNC10112646 and UNC10225498 Figures 8A and 8B results for high performance liquid chromatography (HPLC) analysis for the effects of UNC10112646 or UNC10225498 on PPIP5K activity and IP6K activity Figures S1-S4 for experimental results further characterizing UNC10112646, UNC10225498, and other inhibitors, when the results were not supported by the experimental records. As a result of Respondent's admission, NIH recommended that the PLoS One 2016 paper be retracted. Dr. Baughman has entered into a Voluntary Settlement Agreement with ORI, in which she voluntarily agreed: (1) To have her research supervised for a period of three (3) years beginning on May 17, 2017; Respondent agreed to ensure that prior to the submission of an application for U.S. Public Health Service (PHS) support for a research project on which Respondent's participation is proposed and prior to Respondent's participation in any capacity on PHS-supported research, Respondent shall ensure that a plan for supervision of Respondent's duties is submitted to ORI for approval; the supervision plan must be designed to ensure the scientific integrity of Respondent's research contribution; Respondent agreed that she will not participate in any PHS-supported research until a plan for supervision is submitted to and approved by ORI; Respondent agreed to maintain responsibility for compliance with the agreed upon supervision plan; (2) that for a period of three (3) years beginning on May 17, 2017, any institution employing her shall submit, in conjunction with each application for PHS funds, or report, manuscript, or abstract involving PHS-supported research in which Respondent is involved, a certification to ORI that the data provided by Respondent are based on actual experiments or are otherwise legitimately derived and that the data, procedures, and methodology are accurately reported in the application, report, manuscript, or abstract; (3) to exclude herself from serving in any advisory capacity to PHS including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant for a period of three (3) years, beginning on May 17, 2017; and (4) as a condition of the Agreement, to the retraction or correction of PLoS One 11(10):e0164378d, 2016 (PMID: 27736936).]]> Tue, 20 Jun 2017 00:00:00 -0700 2017-12744 Notice https://www.gpo.gov/fdsys/pkg/FR-2017-06-20/pdf/2017-12744.pdf